DecisionDx-Melanoma Test Outperforms Existing Methods in Identifying Low-Risk Melanoma Patients

A new study published in Cancer Diagnosis & Prognosis shows that Castle Biosciences' DecisionDx-Melanoma test surpasses both American Joint Committee ...